Drug intelligence / Profile preview

HGP-1909

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

HGP-1909 is a small molecule drug developed by Hanmi Pharmaceutical. It is being investigated primarily for the treatment of hypercholesterolemia, which falls under the broader therapeutic area of endocrinology and metabolic diseases. As of March 2025, its highest global R&D status is "Pending," with clinical development having reached Phase 1 in South Korea. The specific mechanism of action and molecular targets have not been publicly disclosed.

Beyond the preview

Go deeper on HGP-1909.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP-1909.

Explore the full profile